Comparison of the efficacy and safety of 0.1% tacrolimus ointment and 0.1% mometasone furoate cream for adult vitiligo: A single-blinded pilot study

作者：Silpa Archa Narumol; Nitayavardhana Sunatra; Thanomkitti Kanchalit; Chularojanamontri Leena; Varothai Supenya; Wongpraparut Chanisada^*

来源：Dermatologica Sinica, 2016, 34(4): 177-179.

DOI：10.1016/j.dsi.2016.05.005

• calcineurin inhibitor
• corticosteroids
• mometasone
• tacrolimus
• vitiligo

Topical tacrolimus has demonstrated efficacy in vitiligo. This study compared the efficacy and safety of 0.1% tacrolimus ointment with 0.1% mometasone furoate cream in adult vitiligo. We enrolled patients with symmetrical, nonacral vitiligo, and the patients on each side were randomized to receive either 0.1% tacrolimus ointment or 0.1% mometasone furoate cream, applied twice daily for 6 months. Repigmentation outcome at 6 months was compared with baseline. Of 18 cases, 22% and 33% in tacrolimus and mometasone groups, respectively, displayed more than 50% repigmentation (p > 0.05). Telangiectasia was presented in one-third of cases on the mometasone-treated side. Both treatments were effective in vitiligo; however, 0.1% tacrolimus ointment has fewer adverse effects.

• 出版日期2016-12